Single-use technology has become the default manufacturing platform across much of bioprocessing, and the films that form bioreactor bags, tubing, and storage containers are not interchangeable commodities. The specific polymer construction of a single-use film determines whether it protects the biologic inside it or quietly compromises it — and materials science in this space has advanced considerably over the past decade as more biopharma customers have come to understand how film composition, plasticizers, and additives affect the cells and molecules in contact with them.
What Polymers Are Most Commonly Used in Single-Use Films?
Although hundreds of distinct films are available for bioprocessing applications, the films favored by bioprocessing firms tend to draw from a relatively small set of base polymers, often combined in multi-layer constructions rather than used alone. Polyethylene (“PE”) is the most widely used thermoplastic in single-use bioprocessing by sales volume, prized for its chemical inertness, flexibility, and compatibility with a wide range of biological materials. Ethylene vinyl acetate (“EVA”) is frequently blended with or layered alongside PE to improve flexibility and seal strength, particularly in applications requiring repeated flexing, such as bioreactor bags subjected to rocking or stirring motion.
Where gas permeability is a concern, manufacturers often incorporate ethylene vinyl alcohol (“EVOH”) as a barrier layer. EVOH provides excellent resistance to oxygen transmission, which matters considerably for oxygen-sensitive cell cultures and for any application where maintaining a controlled atmosphere inside the single-use container is critical to product stability. Polyamide, commonly known as nylon, appears in some multi-layer film constructions where additional mechanical strength or puncture resistance is required, particularly for larger-volume bags subject to handling stress during fill, transport, and storage.
Why Are Most Bioprocessing Films Multi-Layer Constructions Rather Than a Single Polymer?
No single polymer optimizes for every property a bioprocessing application requires simultaneously — flexibility, gas barrier performance, mechanical strength, optical clarity for visual inspection, and chemical compatibility with the biologic in contact with the film often pull in different directions. Multi-layer film construction allows manufacturers to assign each required property to a different layer: an inner contact layer optimized for biocompatibility and low extractables, a barrier layer optimized for gas transmission control, and an outer structural layer optimized for mechanical strength and puncture resistance. This layered approach is why understanding “the polymer” used in a given single-use film is often less useful than understanding the full film construction and which polymer is doing which job within it.
What Role Do Plasticizers and Additives Play, and What Risks Do They Introduce?
Stabilizers and additives are incorporated into bioprocessing films to achieve specific functional performance based on application needs, but their use involves real trade-offs that bioprocessing customers and suppliers both need to understand. Additives can meaningfully improve a film’s strength, durability, flexibility, and temperature sensitivity, and can enhance optical visibility for visual inspection of contents. They can also improve gas permeation control, oxygenation characteristics, fluid absorption behavior, vapor barrier performance, and UV transmittance — all properties that matter for specific bioprocessing applications.
The trade-off is leachables risk. Additives and plasticizers incorporated into a film can, under certain conditions, migrate out of the polymer matrix and into the biologic or process fluid in contact with the film — a phenomenon known as leaching. Leachables are a significant concern in bioprocessing because they can interact with sensitive biological products in ways that are difficult to predict and potentially difficult to detect until later in development or even after a batch has already been processed. This is why extractables and leachables testing has become a standard, expected component of single-use film qualification, and why biopharma customers increasingly scrutinize a film’s full additive package — not just its base polymer — during supplier evaluation.
What Risk Does Polymer Supply Disruption Introduce?
Beyond the chemical and leachables risk discussed above, single-use film polymers carry a second, often underestimated risk category: raw material supply continuity. Specialty resins used in bioprocessing-grade films are frequently produced at a small number of manufacturing sites globally, and some polymer or additive components used in higher-performance film constructions have only one or two qualified commercial sources. A disruption at one of these upstream resin production sites — a force majeure event, a plant shutdown, a feedstock shortage — can cascade through the entire single-use film supply chain, affecting multiple film manufacturers and, in turn, every biologics manufacturer relying on films built from that resin.
This risk is compounded by the qualification burden described earlier: because a film’s extractables and leachables profile is specific to its exact construction, a biopharma manufacturer cannot simply substitute an alternate resin source without triggering re-qualification testing, a process that can take months and, depending on the product’s regulatory stage, may require regulatory notification or approval before the substitute material can be used in commercial manufacturing. This means polymer supply risk is not just a single-use film manufacturer’s problem to manage — it is a risk that propagates directly to the biologics manufacturer’s own production continuity, often with limited visibility into how concentrated or fragile the upstream resin supply chain actually is until a disruption occurs. Biopharma customers serious about managing this risk increasingly ask single-use film suppliers directly about resin source concentration and contingency planning, treating it as a qualification criterion in its own right rather than an assumed given.
What Happens When a Polymer or Additive Changes?
Even a seemingly minor change to a single-use film’s polymer source, additive package, or manufacturing process can trigger a meaningful re-qualification burden for the biopharma customer using it. Because extractables and leachables behavior is specific to the exact film construction tested, a supplier-side change — a new resin lot from a different manufacturing site, a reformulated additive package intended to improve a single property — can invalidate previously generated leachables data, even when the change appears immaterial from a specifications standpoint. This is why bioprocessing customers expect suppliers to maintain rigorous change control and to proactively disclose any modification to film construction, regardless of how minor it may seem from the supplier’s side. A supplier who changes a raw material source without notifying affected customers creates regulatory and quality risk that can take months to identify and resolve — risk that falls almost entirely on the customer using the film in a qualified, validated process.
How Should Bioprocessing Customers Evaluate Single-Use Film Suppliers?
Given the materials science complexity described above, customers evaluating single-use film suppliers need visibility into more than a film’s headline specifications. A rigorous evaluation typically includes documented extractables and leachables data specific to the film construction in question, clarity on which polymer layer is responsible for which functional property, and evidence that the supplier maintains consistent raw material sourcing for each polymer and additive in the construction — since a substitution at any layer, even one that appears minor, can change the film’s leachables profile and require re-qualification.
Suppliers who can speak fluently to the specific role of each layer in their film construction, and who proactively share extractables and leachables data rather than waiting to be asked, are positioned more strongly in this kind of technical evaluation than suppliers who treat their film construction as a competitive black box. In a market where the consequences of an unanticipated leachable reaching a clinical or commercial biologic can be severe, transparency about film composition has become as much a competitive differentiator as the film’s raw performance specifications.